Finch Therapeutics Announces $90 Million Financing to Advance Pipeline of Investigational Oral Microbiome Drugs

Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis B Somerville, MA, September 17, 2020 – Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today[…]